GPC2-Targeted CAR T Cells Engineered with NFAT-Inducible Membrane-Tethered IL15/IL21 Exhibit Enhanced Activity

Reona Okada1, Jeyshka M Reyes-González1, Constanza Rodriguez1

  • 1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

PubMed

Insights

Engineered chimeric antigen receptor (CAR) T cells targeting GPC2 show promise for high-burden neuroblastoma. An NFAT-inducible cytokine expression strategy improved efficacy and tolerability in preclinical models.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Neuroblastoma is a severe childhood cancer with poor prognosis.
  • Current chimeric antigen receptor (CAR) T-cell therapies show limited success in high-tumor-burden neuroblastoma.
  • Optimizing CAR T cells, including cytokine enhancement, is crucial for improving treatment outcomes.

Purpose of the Study:

  • To evaluate the efficacy of glypican 2 (GPC2)-targeted CAR T cells enhanced with interleukin-15 (IL15) and interleukin-21 (IL21) for treating high-burden neuroblastoma.
  • To compare three strategies for cytokine expression: constitutive secretion, constitutive membrane-tethered expression, and NFAT-inducible membrane-tethered expression.
  • To assess the safety and tolerability of these enhanced CAR T cells in preclinical models.

Main Methods:

  • Engineered GPC2-CAR T cells with different IL15/IL21 expression strategies were developed.
  • In vitro and in vivo efficacy was tested using high neuroblastoma burden xenograft models.
  • Single-cell RNA sequencing was employed to analyze the tumor microenvironment and effector cell profiles.

Main Results:

  • All three GPC2-CAR T-cell variants significantly improved tumor killing compared to control CAR T cells.
  • The NFAT-inducible GPC2-CAR T-cell group showed reduced morbidity and mortality associated with anorexia.
  • NFAT-inducible GPC2-CAR T cells induced an immunosuppressive tumor microenvironment profile post-regression, correlating with prolonged survival.

Conclusions:

  • NFAT-inducible co-expression of tethered IL15/IL21 enhances GPC2-CAR T-cell efficacy against high-burden neuroblastoma.
  • This strategy demonstrated acceptable tolerability in preclinical models.
  • Further research is needed to validate these findings for clinical application.

Related Concept Videos